Sotyktu, deucravacitinib
Named-patient access overview. Sotyktu is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Sotyktu
Sotyktu (deucravacitinib) is manufactured by Bristol Myers Squibb and indicated for Moderate-to-severe plaque psoriasis in adults. It is an oral small molecule (TYK2 inhibitor) approved by the US FDA in 2022 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Sotyktu
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Sotyktu for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Sotyktu is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. Sotyktu country deep-dives are not yet published; we are expanding coverage as the cohort grows. If you are pursuing Sotyktu for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Sotyktu is in coordination scope for the first cohort. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Sotyktu
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Sotyktu if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Sotyktu for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Sotyktu through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Sotyktu. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Sotyktu through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Sotyktu to a patient?
Reserve Meds sources Sotyktu from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Sotyktu cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Sotyktu?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.